TY - JOUR
T1 - Suboccipital decompression for Chiari I malformation
T2 - Outcome comparison of duraplasty with expanded polytetrafluoroethylene dural substitute versus pericranial autograft
AU - Attenello, Frank J.
AU - McGirt, Matthew J.
AU - Garcés-Ambrossi, Giannina L.
AU - Chaichana, Kaisorn L.
AU - Carson, Benjamin
AU - Jallo, George I.
N1 - Funding Information:
Acknowledgments This work was funded in part by the American Syringomyelia Alliance Project Monkton Institute CNS Fellowship Disclosures Matthew McGirt is a consultant for W.L. Gore & Associates, Inc.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - Objective: Treatment failure for Chiari decompression is frequently associated with scarring, intradural adhesions, and recurrent loss of hindbrain space. While autograft has been our standard for hindbrain duraplasty, we investigated whether introducing anti-adhesive synthetic GORE PRECLUDE® MVP® Dura Substitute (expanded polytetrafluoroethylene [ePTFE] graft) was associated with improved patient outcomes. Materials and methods: We retrospectively reviewed records of patients undergoing first-time suboccipital decompression/duraplasty for Chiari-I malformation utilizing ePTFE graft or pericranial autograft. Magnetic resonance imaging (MRI) at last follow-up was assessed for: (1) recurrent loss of dorsal hindbrain cerebrospinal fluid (CSF) space/CSF flow(cine-MR) at duraplasty site, (2) pseudomeningocele, or (3) syringomyelia improvement. Symptom recurrence warranting revision surgery was compared between cohorts. Results: Sixty-seven patients (age 11±5 years) underwent duraplasty with pericranial autograft (n=40) or ePTFE graft (n=27). Perioperative morbidity did not differ between cohorts. No patients receiving ePTFE graft experienced incisional CSF leak, surgical site infection, or symptomatic pseudomeningocele. At median 8 months postoperatively, all (100%) patients with ePTFE graft maintained physiological CSF flow/decompressed hindbrain CSF space on cine-MRI versus 32 (79%) patients receiving pericranial autograft (p<0.05). Radiographic syrinx improvement occurred in 80% of patients with ePTFE graft and 52% of patients with pericranial autograft (median time to improvement: 5 vs 12 months, respectively, p<0.05). At median 16 months postoperatively, four (10%) patients with pericranial autograft required revision decompression versus 0 (0%) patients with ePTFE graft (p=0.090). Conclusion: Duraplasty utilizing ePTFE graft was associated with improved maintenance of hindbrain space, accelerated syringomyelia improvement, and a trend toward decreased treatment failure versus pericranial autograft. Future studies of long-term outcome are warranted to confirm observed effects. Synthetic ePTFE graft is a safe alternative for duraplasty in the setting of Chiari malformation.
AB - Objective: Treatment failure for Chiari decompression is frequently associated with scarring, intradural adhesions, and recurrent loss of hindbrain space. While autograft has been our standard for hindbrain duraplasty, we investigated whether introducing anti-adhesive synthetic GORE PRECLUDE® MVP® Dura Substitute (expanded polytetrafluoroethylene [ePTFE] graft) was associated with improved patient outcomes. Materials and methods: We retrospectively reviewed records of patients undergoing first-time suboccipital decompression/duraplasty for Chiari-I malformation utilizing ePTFE graft or pericranial autograft. Magnetic resonance imaging (MRI) at last follow-up was assessed for: (1) recurrent loss of dorsal hindbrain cerebrospinal fluid (CSF) space/CSF flow(cine-MR) at duraplasty site, (2) pseudomeningocele, or (3) syringomyelia improvement. Symptom recurrence warranting revision surgery was compared between cohorts. Results: Sixty-seven patients (age 11±5 years) underwent duraplasty with pericranial autograft (n=40) or ePTFE graft (n=27). Perioperative morbidity did not differ between cohorts. No patients receiving ePTFE graft experienced incisional CSF leak, surgical site infection, or symptomatic pseudomeningocele. At median 8 months postoperatively, all (100%) patients with ePTFE graft maintained physiological CSF flow/decompressed hindbrain CSF space on cine-MRI versus 32 (79%) patients receiving pericranial autograft (p<0.05). Radiographic syrinx improvement occurred in 80% of patients with ePTFE graft and 52% of patients with pericranial autograft (median time to improvement: 5 vs 12 months, respectively, p<0.05). At median 16 months postoperatively, four (10%) patients with pericranial autograft required revision decompression versus 0 (0%) patients with ePTFE graft (p=0.090). Conclusion: Duraplasty utilizing ePTFE graft was associated with improved maintenance of hindbrain space, accelerated syringomyelia improvement, and a trend toward decreased treatment failure versus pericranial autograft. Future studies of long-term outcome are warranted to confirm observed effects. Synthetic ePTFE graft is a safe alternative for duraplasty in the setting of Chiari malformation.
KW - Chiari malformation
KW - Duraplasty
KW - Gore-tex
KW - Pericranium
KW - ePTFE
UR - http://www.scopus.com/inward/record.url?scp=58049182464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58049182464&partnerID=8YFLogxK
U2 - 10.1007/s00381-008-0700-y
DO - 10.1007/s00381-008-0700-y
M3 - Article
C2 - 18769929
AN - SCOPUS:58049182464
VL - 25
SP - 183
EP - 190
JO - Child's Nervous System
JF - Child's Nervous System
SN - 0256-7040
IS - 2
ER -